New eTheRNA led international consortium to develop COV-2 mRNA vaccine CV-19

eTheRNA Immunotherapies, a clinical stage company developing vaccines and immunotherapies from its proprietary mRNA TriMix platform, has announced that a consortium has been formed with North American and European partners to develop a novel mRNA vaccine against CoV-2 and preclinical development has started. Chinese partners may be added in the consortium in due course.

Administered intranasally, the proposed vaccine is intended primarily for high risk populations such as healthcare workers and families of confirmed cases.

It is also designed to be protective against future variations of the virus by targeting conserved epitopes from the whole CoV-2 genome. eTheRNA and its partners EpiVax, Nexelis, REPROCELL and CEV have extensive experience in the mRNA vaccine field and this will help accelerate progress towards clinical trials with patient enrolment expected in early 2021.

Steven Powell, eTheRNA’s CEO, explained the aims of the consortium: “Viral variation means traditional medicinal and preventive vaccine approaches may fall short when confronted with seasonal or outbreak situations.”

“A vaccine to defend against current and future outbreaks of coronavirus and other respiratory viral pathogens should be robust against viral genome changes, provide a platform that enables rapid introduction of a new viral target, be easy and safe to administer and be scaleable and suitable for stockpiling. The innovative vaccine program we have started with our partners incorporates all of these essential features.”

However, viral variation may greatly reduce the effectiveness of this approach.

For example, the SARS-CoV-2 outer surface spike protein (S) is less than 40% homologous to SARS-CoV-1. Furthermore, it has also been reported in several cases that vaccines with suboptimal antibody response (too low or not neutralising) have facilitated viral entry and been linked to disease enhancement.

The eTheRNA consortium’s approach selects conserved epitopes from the whole viral genome. Creating a vaccine that mounts a strong cellular (T cell) based response against these epitopes offers a better chance to overcome viral variability.

Intranasal delivery has been chosen since the mucosa of the upper respiratory tract are the immune system’s primary line of defence. A strong nasal T cell effector and memory response is claimed to fight viral replication, colonisation of the lung and thus disease. mRNA has also been demonstrated to induce strong T cell responses by intranasal delivery.

The development programme has been initiated and is focused on a vaccine candidate that integrates three different technologies:

  • eTheRNA’s proprietary Trimix technology: an mRNA-based vaccine adjuvant that stimulates dendritic cells into activating a strong CD4 and CD8 T cell response
  • a combination of T cell epitopes from the virus brought together on a single mRNA construct; Ffor SARS-CoV-2, this will employ an in silico epitope prediction and design approach from EpiVax Inc. to identify the target
  • an intranasal vaccine delivery platform using a nasal atomiser and a proprietary formulation that delivers the mRNA to the nasal mucosa and optimises expression; one of the most promising formulation candidates is being repurposed for clinical use in collaboration with REPROCELL.

“Although valuable initiatives and strong support are being deployed into the development of medicinal and vaccine solutions for immediate use against SARS-CoV-2, it is also important that development of solutions for the longer-term should also start as soon as possible,” concluded Powell. “Our target is to bring this into clinical testing in early 2021.”

News source: Manufacturing Chemist

virus

Other News

Follow NETPark On Social Media

Keep up to date with the latest NETPark news and events.

NETPark Logo

The North East Technology Park provides a dynamic and supportive environment to accelerate the growth of ambitious, innovative, high tech companies into global markets. NETPark encourages collaborative multidisciplinary links, driving innovation, enterprise and economic prosperity.
We provide companies with access to a focused and international community where talent flourishes, ideas are generated and businesses have the support and resources to compete with the best in the world.

NETPark North East Technology Park

NETPark, North East Technology Park,
Sedgefield, County Durham TS21 3FD

Call Us: (+44) 01740 625250
Email: enquiries@northeasttechnologypark.com
Web: northeasttechnologypark.com

CPI has developed a specialist offering to support SMEs looking to develop their printable electronics applications and our partnership with Business Durham has been instrumental in attracting several SMEs to locate here in the region.

Dr Jon Helliwell, - Director of Printable Electronics, CPI

It fits perfectly for us that we’re surrounded by like-minded companies at NETPark. There are a number of highly skilled people in the area who can help us grow our business. The facilities and services offered by NETPark are first class, they make office life simple and engaging.

Stuart Wilson, - CEO, Ascarii

We initially came because of the printable electronics centre but access to a highly skilled semi conductor workforce in the North East has been a key factor in us staying and growing here, as well as the value for money office space and the access to funding.

Ken Williamson, - COO, PragmatIC Printing

The proximity to the universities and the infrastructure are very important factors. Ultimately having a presence in Europe is very valuable to us and we intend to stay at NETPark for many years to come.

Dr Arnab Basu, - CEO, Kromek

The quality of the facilities at NETPark and the attitude of staff is first class. It has a really dynamic, innovative atmosphere.

Dr Neil Loxley, - Chief executive, IBEX

Access to quality facilities was one of the main drivers for deciding to locate the business at the NETPark. We have been able to use this as a launch pad to link into support from CPI and world-class expertise from Durham University.

Steve Clements, - Managing Director, aXenic
2020-03-31T09:22:32+00:00
Go to Top